Varenicline for Smoking Cessation in Pancreatitis

StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Mayo Clinic

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Secondary endpoints revised (3)
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Mayo Clinic
1,024 trials monitored
See 128 trials at risk
This study will look at how safe and how effective varenicline, a commonly used medication for smoking cessation, is in helping patients with pancreatitis stop smoking cigarettes. Individuals who agree to be part of the study will be treated with varenicline for 12 weeks, after which the investigators will see how many have stopped smoking.
Trial Details
NCT Number NCT07874841
Lead Sponsor Mayo Clinic
Conditions
(from sponsor)		 Pancreatitis, Chronic Pancreatitis, Acute Pancreatitis (AP), Recurrent Acute Pancreatitis
Related terms Pancreatitis, Pancreatitis, Chronic, Smoking Cessation
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov